NCT01357655 2017-03-14
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
Bristol-Myers Squibb
Phase 2 Terminated
Clinical Trials
6 trialsNCT00884546 2016-09-30
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
Bristol-Myers Squibb
Phase 1 Completed
NCT01218477 2016-06-17
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00670189 2014-08-15
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT00909402 2013-06-21
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Bristol-Myers Squibb
Phase 1 Completed
NCT01413906 2013-06-03
Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed